Impact of HER2-low and HER2-zero status on outcomes: A multicenter propensity-score matched study

被引：0
|
作者：
Cha, C. D. [1 ]
Kim, K. E. [2 ]
Kim, J. [3 ]
Um, E. [4 ]
Choi, N. [5 ]
Lee, J. [2 ]
Gwak, G. [3 ]
Kim, J. I. [4 ]
Chung, M. S. [1 ]
机构：
[1] Hanyang Univ, Coll Med, Surg, Seoul, South Korea
[2] Inje Univ, Coll Med, Surg, Haeundae Paik Hosp, Busan, South Korea
[3] Inje Univ, Sanggye Paik Hosp, Sch Med, Surg, Seoul, South Korea
[4] Inje Univ, Ilsan Paik Hosp, Ilsan, South Korea
[5] Hanyang Univ, Med Res Collaborating Ctr, Seoul, South Korea
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.104089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P248
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
    Xia, Lin-Yu
    Cao, Xu-Chen
    Yu, Yue
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [12] Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
    Ko, Heidi Chwan
    Seager, R. J.
    Pabla, Sarabjot
    Senosain, Maria-Fernanda
    Van Roey, Erik
    Gao, Shuang
    Strickland, Kyle C.
    Previs, Rebecca Ann
    Green, Michelle F.
    Cooper, Maureen
    Nesline, Mary K.
    Hastings, Stephanie B.
    Amoah, Kobina Agyaful
    Zhang, Shengle
    Conroy, Jeffrey M.
    Jensen, Taylor J.
    Eisenberg, Marcia
    Caveney, Brian
    Severson, Eric A.
    Ramkissoon, Shakti
    Gandhi, Shipra
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 483 - 495
  • [13] Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
    Kang, Sora
    Lee, So Heun
    Lee, Hee Jin
    Jeong, Hyehyun
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Gong, Gyungyub
    Kim, Hak Hee
    Lee, Saebyeol
    Lee, Jongwon
    Kim, Sung-Bae
    EUROPEAN JOURNAL OF CANCER, 2023, 191
  • [14] Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
    Kang, S.
    Lee, S. H.
    Lee, H. J.
    Jeong, H.
    Jeong, J-H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Kim, H. H.
    Lee, S.
    Lee, J.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2023, 34 : S305 - S305
  • [15] Neoadjuvant chemotherapy ef fi cacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China
    Zhao, Shaorong
    Wang, Yuyun
    Zhou, Angxiao
    Liu, Xu
    Zhang, Yi
    Zhang, Jin
    PEERJ, 2024, 12
  • [16] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [17] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [18] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constantin, Guillaume
    Roussot, Nicolas
    Ilie, Alis
    Bergeron, Anthony
    Arnould, Laurent
    Beltjens, Francoise
    Desmoulin, Isabelle
    Mayeur, Didier
    Kaderbhai, Coureche
    Hennequin, Audrey
    Jankowski, Clementine
    Padeano, Marie Martine
    Costaz, Helene
    Amet, Alix
    Coutant, Charles
    Coudert, Bruno
    Bertaut, Aurelie
    Ladoire, Sylvain
    BREAST CANCER, 2023, 30 (06) : 997 - 1007
  • [19] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Silvia Mihaela Ilie
    Nathalie Briot
    Guillaume Constantin
    Nicolas Roussot
    Alis Ilie
    Anthony Bergeron
    Laurent Arnould
    Françoise Beltjens
    Isabelle Desmoulin
    Didier Mayeur
    Courèche Kaderbhai
    Audrey Hennequin
    Clémentine Jankowski
    Marie Martine Padeano
    Helène Costaz
    Alix Amet
    Charles Coutant
    Bruno Coudert
    Aurélie Bertaut
    Sylvain Ladoire
    Breast Cancer, 2023, 30 : 997 - 1007
  • [20] Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer
    Almstedt, Katrin
    Heimes, Anne-Sophie
    Kappenberg, Franziska
    Battista, Marco J.
    Lehr, Hans-Anton
    Krajnak, Slavomir
    Lebrecht, Antje
    Gehrmann, Mathias
    Stewen, Kathrin
    Brenner, Walburgis
    Weikel, Wolfgang
    Rahnenfuehrer, Joerg
    Hengstler, Jan G.
    Hasenburg, Annette
    Schmidt, Marcus
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : 10 - 19
12345